Viatris Stock News

This recently approved generic drug could benefit 5% to 15% of the overall population.

Biocon share price: Biocon shares traded lower on Wednesday on dull brokerage commentary after subsidiary Biocon Biologics entered into a definitive agreement with Viatris to acquire the US-based company''s biosimilars business.

Biocon Biologics Ltd has agreed to acquire the biosimilar assets of its partner Viatris Inc. for $3.34 billion in cash and stocks, a move that will give the Indian company access to developed markets in North America and Europe.

Biocon - Biosimilar Deal With Viatris Completes The Value Chain In Its Biologics Business: Motilal Oswal

Analysts said if Biocon manages to direct business growth in the right manner, it could be a game changer

Viatris Inc. (NASDAQ: VTRS) shares have weakened more than 20% after the company reported fourth-quarter results this Monday. Fourth-quarter results and revenue outlook disappointed several banks and

Viatris (VTRS) continues to trade lower in morning hours on Tuesday as several Wall Street firms issued downgrades on the generics drugmaker following its Q4 2021 results…

Viatris Stock: Why So Serious? Let's Put A Buy On Your Portfolio

ET Intelligence Group: The Street frowned upon Indian drug major Biocon''s move to buy the biologic business of its US business partner Viatris through its subsidiary Biocon Biologics (BBL). The Biocon stock lost 11.2% on Monday as analysts were concerned about high deal valuations, an increase in Biocon''s debt burden and execution risks in a still-emerging and complex area of biosimilars.The $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of Biocon. With this deal, BBL is buying out the biosimilar portfolio of its long-time collaborator Mylan that merged with Pfizer''s Upjohn business to become Viatris. The acquisition will allow BBL to acquire regulatory, supply chain and commercialisation capabilities in the developed markets. It also gets rights to key in-licensed therapies including biosimilar Adalimumab (used to treat autoimmune conditions) and an option to acquire the Viatris''s rights for biosimilar Aflibercept (used to treat macular disorders) at a cost of $175 million. 89914048BBL has a portfolio of 20 biosimilars - out of which seven have been commercialised.For the December quarter, it earned revenues of ₹981 crore, 28% higher than a year ago, with a core operating profit (Ebitda) margin of 38%.

Kiran Mazumdar-Shaw has made one of her boldest moves, acquiring a business that’s about the size of her own company for $3. 3 billion. Biocon Biologics, a subsidiary of MazumdarShaw’s Biocon, is acquiring the biosimilar assets of USbased Viatris (formerly Mylan).

BBL acquires Viatris’ global biosimilars business with an estimated revenue of $875 million and EBITDA of $200 million for CY 2022 and estimated to exceed $1 billion in revenue next year.

The proposed settlement, which requires a judge’s approval, would resolve a legal battle that began after the company, in 2016, raised the price for two EpiPens to $608 from $100.

Biocon shares posted their biggest single-day fall since August 2015.